AI Therapeutics Logo.jpg
AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)
April 25, 2022 10:30 ET | AI Therapeutics, Inc.
GUILFORD, Conn., April 25, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., an AI driven clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, today announced the...
New Logo.png
Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board
April 14, 2022 07:30 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 14, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Aru Narendran, MD, PhD to the Company’s Scientific Advisory Board. Dr. Narendran is a...
22157.jpg
2021 Outlook on Pediatrics Partnering Deals - In-depth Review of Deals Entered into by the Top 25 Most Active Dealmakers
January 04, 2022 05:23 ET | Research and Markets
Dublin, Jan. 04, 2022 (GLOBE NEWSWIRE) -- The "Global Pediatrics Partnering 2010-2021: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering. Global...
22157.jpg
Global Pediatrics Partnering Directory 2010-2021: Comprehensive Access to 500+ Pediatrics Deal Records
March 12, 2021 07:08 ET | Research and Markets
Dublin, March 12, 2021 (GLOBE NEWSWIRE) -- The "Global Pediatrics Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. Global...
THE ACCESS TO CHILDHOOD CANCER ESSENTIALS (ACCESS) INITIATIVE ANNOUNCES TRANSFORMATIVE PROGRAMS TO INCREASE ACCESS TO CRITICAL MEDICINES
January 14, 2019 09:00 ET | The American Childhood Cancer Organization
Washington D.C., Jan. 14, 2019 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE – January 13, 2019 – Washington, D.C.  Access to Childhood Cancer Essentials (ACCESS) today announced two initiatives with...